Across TCGA pan-cancer cohorts, SUN5 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SUN5’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where SUN5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SUN5 is over-expressed in tumor.
PRAD and KIRC are the cancer types where SUN5 tumor–normal differential expression is most reproducible.